Pfizer Historical Cash Flow
| PFE Stock | USD 25.40 0.14 0.55% |
Analysis of Pfizer cash flow over time is an excellent tool to project Pfizer Inc future capital expenditures as well as to predict the amount of cash needed to cover cost of sales, R&D expenses or production expansions. Investors should almost always look for trends in cash flow indicators such as Other Cashflows From Financing Activities of 74.8 B or Depreciation of 4.1 B as it is a great indicator of Pfizer ability to facilitate future growth, repay debt on time or pay out dividends.
Financial Statement Analysis is much more than just reviewing and examining Pfizer Inc latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Pfizer Inc is a good buy for the upcoming year.
Pfizer |
About Pfizer Cash Flow Analysis
The Cash Flow Statement is a financial statement that shows how changes in Pfizer balance sheet and income statement accounts affect cash and cash equivalents. It breaks the analysis down to operating, investing, and financing activities. One of the most critical aspects of the cash flow statement is liquidity, which is the degree to which Pfizer's non-liquid assets can be easily converted into cash.
Pfizer Cash Flow Chart
Pfizer Cash Flow Statement became part of mandatory reporting in 1987. It is now one of three main statements in accounting used to measure how well a company manages its liquidity and overall cash position. The rate of cash utilization and preservation is now part of the leading indicators of a healthy entity, and the Pfizer Inc Cash Flow Statement shows how well the company generates cash to payout debt obligations or to cover ongoing operating expenses.
At present, Pfizer's Change In Cash is projected to increase significantly based on the last few years of reporting. The current year's Other Cashflows From Financing Activities is expected to grow to about 74.8 B, whereas Free Cash Flow is forecasted to decline to about 4.6 B. Add Fundamental
Free Cash Flow
The amount of cash a company generates after accounting for cash outflows to support operations and maintain its capital assets.Begin Period Cash Flow
The amount of cash a company has at the beginning of a financial reporting period. It serves as the starting point for calculating the period's cash flow from operations, investing, and financing activities.Dividends Paid
The total amount of dividends that a company has paid out to its shareholders over a specific period.Capital Expenditures
Capital Expenditures are funds used by Pfizer Inc to acquire physical assets such as property, industrial buildings or equipment. This type of outlay is used by management to increase the scope of Pfizer operations. These expenditures can include everything from repairing an office equipment, building a brand new facility, or writing new software.Most accounts from Pfizer's cash flow statement are interrelated and interconnected. However, analyzing cash flow statement accounts one by one will only give a small insight into Pfizer Inc current financial condition. On the other hand, looking into the entire matrix of cash flow statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Pfizer Inc. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in census. At present, Pfizer's Change In Cash is projected to increase significantly based on the last few years of reporting. The current year's Other Cashflows From Financing Activities is expected to grow to about 74.8 B, whereas Free Cash Flow is forecasted to decline to about 4.6 B.
| 2021 | 2022 | 2023 | 2024 (projected) | Capital Expenditures | 2.7B | 3.2B | 3.9B | 4.1B | Dividends Paid | 8.7B | 9.0B | 9.2B | 5.2B |
Pfizer cash flow statement Correlations
Click cells to compare fundamentals
Pfizer Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Pfizer cash flow statement Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Change To Inventory | (1.1B) | (736M) | (1.1B) | 592M | (1.2B) | (1.1B) | |
| Change In Cash | 125M | 475M | 158M | (1.5B) | 2.4B | 2.6B | |
| Free Cash Flow | 10.0B | 11.6B | 29.9B | 26.0B | 4.8B | 4.6B | |
| Change In Working Capital | (4.0B) | (275M) | 12.8B | (4.5B) | (2.2B) | (2.1B) | |
| Begin Period Cash Flow | 1.2B | 1.4B | 1.8B | 2.0B | 416M | 395.2M | |
| Other Cashflows From Financing Activities | (735M) | 29.1B | 1.0B | 3.6B | 71.3B | 74.8B | |
| Depreciation | 6.0B | 4.8B | 5.2B | 5.1B | 6.3B | 4.1B | |
| Other Non Cash Items | (7.0B) | 3.6B | (4.8B) | 150M | 5.4B | 5.6B | |
| Dividends Paid | 8.0B | 8.4B | 8.7B | 9.0B | 9.2B | 5.2B | |
| Capital Expenditures | 2.6B | 2.8B | 2.7B | 3.2B | 3.9B | 4.1B | |
| Total Cash From Operating Activities | 12.6B | 14.4B | 32.6B | 29.3B | 8.7B | 12.4B | |
| Net Income | 16.3B | 7.0B | 22.5B | 31.4B | 2.1B | 2.0B | |
| Total Cash From Financing Activities | (8.5B) | (9.6B) | (9.8B) | (14.8B) | 26.1B | 27.4B | |
| End Period Cash Flow | 1.4B | 1.8B | 2.0B | 468M | 2.9B | 2.2B | |
| Stock Based Compensation | 718M | 756M | 1.2B | 872M | 525M | 551.3M | |
| Other Cashflows From Investing Activities | (11.1B) | 573M | (318M) | (12.5B) | (11.3B) | (10.7B) | |
| Change To Netincome | 2.9B | 2.9B | (7.3B) | (2.7B) | (2.5B) | (2.3B) | |
| Change To Liabilities | (3.0B) | 1.9B | 1.2B | (803M) | (722.7M) | (686.6M) | |
| Total Cashflows From Investing Activities | (3.9B) | (4.3B) | (22.5B) | (15.8B) | (32.3B) | (30.7B) | |
| Change To Account Receivables | (742M) | (1.2B) | (3.8B) | 261M | 347M | 364.4M | |
| Investments | 9.3B | (2.6B) | (19.5B) | 11.1B | (32.3B) | (30.7B) | |
| Change Receivables | (742M) | (1.2B) | (3.8B) | 261M | 234.9M | 246.6M | |
| Net Borrowings | 8.8B | (12.8B) | (1.1B) | (3.5B) | (3.2B) | (3.0B) | |
| Cash And Cash Equivalents Changes | 158M | 483M | 218M | (1.4B) | (1.2B) | (1.2B) | |
| Cash Flows Other Operating | (7.8B) | 6.9B | 21.4B | 26.9B | 30.9B | 32.5B | |
| Change To Operating Activities | (1.7B) | 1.4B | 16.5B | (6.5B) | (7.5B) | (7.1B) |
Becoming a Better Investor with Macroaxis
Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Pfizer Inc using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.Build Optimal Portfolios
Align your risk with return expectations
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Pfizer Inc. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in census. Note that the Pfizer Inc information on this page should be used as a complementary analysis to other Pfizer's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the My Watchlist Analysis module to analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like.
Complementary Tools for Pfizer Stock analysis
When running Pfizer's price analysis, check to measure Pfizer's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pfizer is operating at the current time. Most of Pfizer's value examination focuses on studying past and present price action to predict the probability of Pfizer's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pfizer's price. Additionally, you may evaluate how the addition of Pfizer to your portfolios can decrease your overall portfolio volatility.
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance |
Is Pfizer's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Pfizer. If investors know Pfizer will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Pfizer listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.76) | Dividend Share 1.64 | Earnings Share 0.37 | Revenue Per Share 10.366 | Quarterly Revenue Growth (0.41) |
The market value of Pfizer Inc is measured differently than its book value, which is the value of Pfizer that is recorded on the company's balance sheet. Investors also form their own opinion of Pfizer's value that differs from its market value or its book value, called intrinsic value, which is Pfizer's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Pfizer's market value can be influenced by many factors that don't directly affect Pfizer's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Pfizer's value and its price as these two are different measures arrived at by different means. Investors typically determine if Pfizer is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Pfizer's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.